Conference appearance puts BillionToOne in focus

BillionToOne (BLLN) is scheduled to present at the 46th Annual William Blair Growth Stock Conference on June 2, 2026. The event often prompts investors to reassess growth stories and valuation.

BillionToOne’s recent trading reflects building momentum, with a 1-day share price return of 4.36%, 7-day return of 8.06% and a 30-day share price return of 36.38% bringing the stock to $98.36, with year to date gains of 10.16% ahead of the William Blair appearance.

If this conference catalyst has you looking beyond a single stock, it could be a good moment to see what else is moving across healthcare AI, starting with 39 healthcare AI stocks.

With BillionToOne trading at $98.36 and an indicated intrinsic discount, along with a gap to analyst targets, the key question is whether the conference can surface hidden value or if the stock already reflects future growth.

Most Popular Narrative: 27.3% Undervalued

At a last close of $98.36 versus a most-followed fair value estimate of $135.29, the current price sits well below that narrative benchmark, putting extra attention on what might be embedded in those expectations as BillionToOne heads into the William Blair conference.

Growing adoption of noninvasive prenatal testing and broader carrier screening, supported by UNITY publications and an exclusive Johnson & Johnson companion diagnostic agreement, can support higher test volumes and ASPs. This would feed directly into revenue and gross margin.

Curious what justifies a higher fair value here? The narrative leans on rapid top line expansion, rising margins and a future earnings profile that assumes materially stronger profitability. The key link between those moving parts is not obvious at first glance.

Result: Fair Value of $135.29 (UNDERVALUED)

However, this hinges on UNITY maintaining pricing power and reimbursement support, as well as on oncology margins improving, both of which could move sentiment sharply either way.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Another View on BillionToOne’s Valuation

The SWS DCF model paints a different picture to the analyst price target. At $98.36, BillionToOne is assessed as trading 51.6% below an estimate of future cash flow value of $203.29, which also supports an “undervalued” label, but raises questions about how aggressive those long term assumptions might be.

Before leaning on any single model, it is worth understanding how the cash flow assumptions and discount rate work together in the SWS DCF model, and where your own expectations differ from those inputs, Look into how the SWS DCF model arrives at its fair value.

Next Steps

With sentiment this mixed, it helps to move fast, review the numbers yourself, and weigh both sides of the story, starting with the 3 key rewards and 2 important warning signs.

Looking for more investment ideas?

If BillionToOne has your attention, do not stop here. Use this momentum to scan fresh opportunities that match your style before others move first.

• Target stronger fundamentals by checking companies in the solid balance sheet and fundamentals stocks screener (47 results) that may handle stress better over time.
• Hunt for potential mispricings by reviewing the 47 high quality undervalued stocks, where quality metrics and current prices can look out of sync.
• Spot under-the-radar stories early by scanning the screener containing 22 high quality undiscovered gems before they attract wider attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.